Pluripotent Stem Cells Models for Huntington's Disease: Prospects and Challenges

Overview

Journal J Genet Genomics

Publisher Science Press

Specialty Genetics

Date 2012 Jul 4

PMID 22749012

Citations 10

Authors

Richard L Carter

Anthony W S Chan

Affiliations

Soon will be listed here.

Abstract

Pluripotent cellular models have shown great promise in the study of a number of neurological disorders. Several advantages of using a stem cell model include the potential for cells to derive disease relevant neuronal cell types, providing a system for researchers to monitor disease progression during neurogenesis, along with serving as a platform for drug discovery. A number of stem cell derived models have been employed to establish in vitro research models of Huntington's disease that can be used to investigate cellular pathology and screen for drug and cell-based therapies. Although some progress has been made, there are a number of challenges and limitations that must be overcome before the true potential of this research strategy is achieved. In this article we review current stem cell models that have been reported, as well as discuss the issues that impair these studies. We also highlight the prospective application of Huntington's disease stem cell models in the development of novel therapeutic strategies and advancement of personalized medicine.

Citing Articles

Investigating the Therapeutics Effects of Oral Cavity Derived Stem Cells on Neurodegenerative Diseases: A Systematic Review.

Uzunoglu-Ozyurek E, Onal G, Dokmeci S Basic Clin Neurosci. 2024; 14(5):565-584.

PMID: 38628839 PMC: 11016878. DOI: 10.32598/bcn.2021.2892.1.

A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders.

Autar K, Guo X, Rumsey J, Long C, Akanda N, Jackson M Stem Cell Reports. 2021; 17(1):96-109.

PMID: 34942087 PMC: 8758945. DOI: 10.1016/j.stemcr.2021.11.009.

Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.

Sawant N, Morton H, Kshirsagar S, Reddy A, Reddy P Mol Neurobiol. 2021; 58(12):6350-6377.

PMID: 34519969 DOI: 10.1007/s12035-021-02556-x.

Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy.

Csobonyeiova M, Polak S, Danisovic L Int J Mol Sci. 2020; 21(6).

PMID: 32213859 PMC: 7139425. DOI: 10.3390/ijms21062239.

Generation of genetically engineered non-human primate models of brain function and neurological disorders.

Park J, Silva A Am J Primatol. 2018; 81(2):e22931.

PMID: 30585654 PMC: 6463491. DOI: 10.1002/ajp.22931.

References

Deng Y, Albin R, Penney J, Young A, Anderson K, Reiner A . Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat. 2004; 27(3):143-64. DOI: 10.1016/j.jchemneu.2004.02.005. View

Zuccato C, Cattaneo E . Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009; 5(6):311-22. DOI: 10.1038/nrneurol.2009.54. View

Hedreen J, Folstein S . Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol. 1995; 54(1):105-20. DOI: 10.1097/00005072-199501000-00013. View

Bachoud-Levi A, Gaura V, Brugieres P, Lefaucheur J, Boisse M, Maison P . Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 2006; 5(4):303-9. DOI: 10.1016/S1474-4422(06)70381-7. View

Koch P, Opitz T, Steinbeck J, Ladewig J, Brustle O . A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc Natl Acad Sci U S A. 2009; 106(9):3225-30. PMC: 2651316. DOI: 10.1073/pnas.0808387106. View

Gil J, Rego A . Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci. 2008; 27(11):2803-20. DOI: 10.1111/j.1460-9568.2008.06310.x. View

Zuccato C, Valenza M, Cattaneo E . Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010; 90(3):905-81. DOI: 10.1152/physrev.00041.2009. View

Johansen K, Wang L, Aasly J, White L, Matson W, Henchcliffe C . Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One. 2009; 4(10):e7551. PMC: 2761616. DOI: 10.1371/journal.pone.0007551. View

Marchetto M, Winner B, Gage F . Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet. 2010; 19(R1):R71-6. PMC: 2875052. DOI: 10.1093/hmg/ddq159. View

10.

Erceg S, Ronaghi M, Stojkovic M . Human embryonic stem cell differentiation toward regional specific neural precursors. Stem Cells. 2008; 27(1):78-87. PMC: 2729673. DOI: 10.1634/stemcells.2008-0543. View

11.

Sapp E, Schwarz C, Chase K, Bhide P, Young A, Penney J . Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol. 1997; 42(4):604-12. DOI: 10.1002/ana.410420411. View

12.

Kim M, Lee S, Chu K, Kim S . Stem cell-based cell therapy for Huntington disease: a review. Neuropathology. 2007; 28(1):1-9. DOI: 10.1111/j.1440-1789.2007.00858.x. View

13.

Huang A, Snyder B, Cheng P, Chan A . Putative dental pulp-derived stem/stromal cells promote proliferation and differentiation of endogenous neural cells in the hippocampus of mice. Stem Cells. 2008; 26(10):2654-63. PMC: 4416417. DOI: 10.1634/stemcells.2008-0285. View

14.

Wu C, Hwang C, Chen S, Yin J, Yang D . Neuroprotective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity: therapeutic implications for Huntington's disease. Ann N Y Acad Sci. 2010; 1201:8-12. DOI: 10.1111/j.1749-6632.2010.05628.x. View

15.

Snyder B, Cheng P, Yang J, Yang S, Huang A, Chan A . Characterization of dental pulp stem/stromal cells of Huntington monkey tooth germs. BMC Cell Biol. 2011; 12:39. PMC: 3189880. DOI: 10.1186/1471-2121-12-39. View

16.

Li T, Zheng J, Xie Y, Wang S, Zhang X, Li J . Transplantable neural progenitor populations derived from rhesus monkey embryonic stem cells. Stem Cells. 2005; 23(9):1295-303. DOI: 10.1634/stemcells.2005-0026. View

17.

Li S, Li X . Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener. 2006; 1:19. PMC: 1764744. DOI: 10.1186/1750-1326-1-19. View

18.

Marchetto M, Brennand K, Boyer L, Gage F . Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum Mol Genet. 2011; 20(R2):R109-15. PMC: 4447776. DOI: 10.1093/hmg/ddr336. View

19.

Reuter I, Tai Y, Pavese N, Chaudhuri K, Mason S, Polkey C . Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry. 2008; 79(8):948-51. DOI: 10.1136/jnnp.2007.142380. View

20.

Menalled L, El-Khodor B, Patry M, Suarez-Farinas M, Orenstein S, Zahasky B . Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis. 2009; 35(3):319-36. PMC: 2728344. DOI: 10.1016/j.nbd.2009.05.007. View